Ivanovich Pirogoff experimented briefly with rectal ether in 1847, first as a liquid and then as a vapour. He reported 81 cases with two deaths and, although he wrote enthusiastically about the technique, does not appear to have continued its use. Ether was extremely irritating to the rectal mucosa and the results were unpredictable. In the early 1900s there was some further experimentation with the technique in Europe but it was never popular. James Gwathmey, an American anaesthetist, devised an oil and ether solution which he used extensively as a rectal induction agent from 1913 onwards. Others embraced the technique and by the 1930s it had become popular in obstetric analgesia where it was used in over 100,000 cases.
In 1922, the Farben Company in Germany produced a watersoluble hypnotic, tribromethanol, a bromine derivative of alcohol. Tribromethanol or E107, like other bromine preparations, was initially used for the treatment of whooping cough. Meanwhile, the director of the pharmacology department, Fritz Eichholtz, discovered that it could be used as a rectal narcotic and recommended it for clinical trials.
These trials were carried out by the surgeon, Otto Butzengeiger, on 300 patients. The Avertin was administered as a 2% solution via a rectal tube in the ward. The maximum dose given was 0.1 g/kg, but the patients were also given premedication with Veronal the night before and Pantopon on the day of the surgery. After administration of the Avertin, the patients were admitted to a special darkened room for 10 minutes prior to surgery. At the end of the operation, the remaining Avertin was sucked out of the rectum and the patient left to sleep off the effects of the drug.
Butzengeiger obtained good results and was extremely cautious, continually monitoring the patient's respiratory rate and pulse rate. Other researchers had more complications and were not enthusiastic about the technique. The principal problems were respiratory depression and severe irritation of the rectal mucosa, both of which could be life-threatening. The celebrated surgeons, Ferdinand Sauerbruch and Hans Killian both condemned the drug as dangerous but, despite negative publicity even in the daily press, the technique gained favour and was used for many decades.
The drug was initially provided as a white, water-soluble crystal which was made into a 2% solution. Heating the solution to 40°C during preparation could create dibromacetaldehyde and hydrobromic acid, the former being highly corrosive to the rectal mucosa. Once this was known it was recommended that the solution be not heated above body temperature and be tested with Congo Red prior to use. D. Howatt describes its use at St George's Hospital in England: "When I was resident anaesthetist at St George's, toxic patients for thyroidectomy were operated first on the morning list. We made up the solution in a thermos flask last thing the night before, and delivered it to the ward with the Congo Red already in it, giving the nurses instructions not to administer it unless the solution had remained pink. This gave us a few more precious minutes in bed in the morning."
Avertin was introduced to the U.K. by Joseph Blomfield and Sir Francis Shipway at the request of Prof. Eichholz. Their initial findings were reported in the Lancet in 1929. They described some of the practical problems associated with the technique. "In making the solution prolonged shaking is needed to avoid the formation of lumps. … Obviously the preparation of a solution which required such considerable time and care-taking as a rule about three quarters of an hour-was a practical disadvantage to Avertin." Later the Bayer company provided Avertin in solution with amylene hydrate which was diluted to a 2.5% solution with distilled water. After the initial trials they continued to use it for nervous patients and especially for thyroidectomies for hyperthyroidism. Shipway safely administered the drug to 1,600 patients but stressed that it should be used with care and moderation.
Another advocate of Avertin in Britain was Sir Robert Macintosh, who reminisced "Then there was that excellent drug Avertin. This put the patient pleasantly to sleep in his bed, and when he woke up it was to become blissfully aware that what he had been dreading was already a thing of the past. A blessing of this sort, now taken for granted, was, at that time, regarded as a near miracle." Interestingly, at the same meeting, Killian made it clear that he had never changed his opinion of the drug, "… first of all the uncontrollable Avertin rectal anaesthesia was developed, but it could not be continued on account of extreme respiratory depression".
Its use had been continued however, and it remained popular for about 40 years, although in the later years it was used in lower concentrations as a background narcotic, amnesic and antiemetic, rather than as the sole induction agent. Avertin was mainly administered by the rectal route, but Martin Kirschner, a German surgeon, used it as an intravenous induction agent. He abandoned Avertin after trying the rectal route but in 1929 he presented his initial work on the intravenous use of Avertin. He infused the drug in a 2-3% solution of NaCl at 0.03 mg/kg, and used it extensively as both an induction agent and the sole agent for brief procedures. His results were good although the complications he reported were not insignificant, with some cases of apnoea and severe drops in blood pressure. More seriously though, he reported a 3% incidence of thrombophlebitis with one fatal pulmonary embolism. One of his patients actually required amputation of his arm after such an event. Despite this he continued with its use intravenously even after the introduction of Evipan in 1932. CHRISTINE BALL, ROD WESTHORPE Geoffrey Kaye Museum of Anaesthetic History
